Article

Eli Lilly has announced plans to build the largest AI supercomputer in the pharmaceutical industry, surpassing Recursion Pharmaceuticals, which currently operates the largest but has no market products or late-stage trials. Eli Lilly aims to leverage extensive data from past clinical trials to enhance its drug discovery process, positioning itself as a more stable investment compared to the high-risk profile of Recursion.